This is why the ChatGPT founder is investing $180M in life extension

Is defying death and making human life longer possible? ChatGPT founder seems to think so. 
Interesting Engineering

Aging is a natural process that we all have to go through, or at least that's what we thought before tech CEOs started investing billions of dollars in anti-aging and longevity research start-ups. Silicon Valley has become a hub for biotech companies that are dedicated to extending human life, and the latest player in this space is Retro Biosciences, a biotech company that has taken on the mission of adding 10 more years to human life.

Retro Biosciences is not alone in this endeavor. Jeff Bezos himself has invested in a similar company called Alton Labs, a research company focused on cellular rejuvenation programming. These tech billionaires are betting big on the idea that science and technology can help us beat mortality and human nature.

But what makes Retro Biosciences unique is their approach to the problem. They plan to use their collective knowledge of cellular reprogramming, autophagy, and plasma-inspired therapeutics to extend human life. But they also have an ace up their sleeve - machine-learning-based computational biology and lab automation.

This is where the investment from Sam Altman, the CEO of OpenAI, comes in. Altman was the mysterious $180 million investor that kickstarted Retro Sciences’ research on the topic. With his investment, Retro Biosciences can now leverage cutting-edge technology to accelerate their research and development.

But is life extension an industry that will be lucrative soon? The answer is not clear yet. While there is certainly a lot of interest in anti-aging and longevity research, it remains to be seen whether science will be able to deliver on its promises. There are also ethical questions to consider - if we are able to extend human life, should we? Who will have access to these treatments, and at what cost?

Despite the uncertainties, tech CEOs continue to invest in this space, and we may see breakthroughs sooner than we thought. Whether or not the industry becomes profitable, the pursuit of extending human life is a noble goal, and one that may ultimately benefit all of humanity.